Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study

0:48 - Repotrectinib was approved in the US in 2023 with a line agnostic indication. Its market authorization application was validated by EMA in 2024, but it is not yet approved in Europe.

 in the repotrectinib naive population, not 51%

8:15 - "Overall we see a potential ROS1 inhibitor that we can qualify as second generation because it's the G3022R resistance mutation and with a very favorable safety profile..." Speaker intended to reference 

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Rafael Fonseca presents the primary results of the phase 3 AURIGA study, which demonstrates the significant improvement in MRD-negative conversion and progression-free survival with subcutaneous daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma post-transplant, shared at the 2024 International Myeloma Society Annual Meeting.